Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence

2. november 2026 oppdatert av: Centessa Pharmaceuticals (UK) Limited

A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Cleminorexton Compared With Placebo in Participants With Central Disorders of Hypersomnolence

Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness [EDS]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.

While all conditions result in feeling sleepy, there are some differences in other common symptoms:

  • NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.
  • NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.

Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable cleminorexton is in NT1 and NT2 and learn about what the drug does to the body. Another goal of the study is to see if cleminorexton can help people with NT1 and NT2 feel less sleepy and make other symptoms better.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

The SAPPHIRE Clinical Trial

The Sponsor may in the future, through a protocol amendment, expand the protocol to include participants with idiopathic hypersomnia (IH) in Cohort C.

Studietype

Intervensjonell

Registrering (Antatt)

222

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forente stater, 35213
        • Rekruttering
        • Birmingham, Alabama
    • Colorado
      • Colorado Springs, Colorado, Forente stater, 80918
        • Rekruttering
        • Colorado Springs, Colorado
    • Florida
      • Brandon, Florida, Forente stater, 33511
        • Rekruttering
        • Brandon, Florida
      • Miami, Florida, Forente stater, 33155
        • Rekruttering
        • Miami, Florida
      • Miami, Florida, Forente stater, 33176
        • Rekruttering
        • Miami, Florida
      • Miami, Florida, Forente stater, 33166
        • Rekruttering
        • Miami, Florida
      • Miami, Florida, Forente stater, 33186
        • Rekruttering
        • Miami, Florida
      • Miami Lakes, Florida, Forente stater, 33014
        • Rekruttering
        • Miami Lakes, Florida
      • Orlando, Florida, Forente stater, 32807
        • Rekruttering
        • Orlando, Florida
      • St. Petersburg, Florida, Forente stater, 33707
        • Rekruttering
        • St. Petersburg, Florida
    • Georgia
      • Atlanta, Georgia, Forente stater, 30328
        • Rekruttering
        • Atlanta, Georgia
      • Rincon, Georgia, Forente stater, 31326
        • Rekruttering
        • Rincon, Georgia
      • Stockbridge, Georgia, Forente stater, 30281
        • Rekruttering
        • Stockbridge, Georgia
    • Michigan
      • Lansing, Michigan, Forente stater, 48911
        • Rekruttering
        • Lansing, Michigan
    • Mississippi
      • Flowood, Mississippi, Forente stater, 39232
        • Rekruttering
        • Flowood Mississippi
    • North Carolina
      • Denver, North Carolina, Forente stater, 28037
        • Rekruttering
        • Denver, North Carolina
      • Huntersville, North Carolina, Forente stater, 28078
        • Rekruttering
        • Huntersville, North Carolina
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45245
        • Rekruttering
        • Cincinnati, Ohio
      • Dublin, Ohio, Forente stater, 43017
        • Rekruttering
        • Dublin, Ohio
    • South Carolina
      • Columbia, South Carolina, Forente stater, 29201
        • Rekruttering
        • Columbia, South Carolina
    • Texas
      • Austin, Texas, Forente stater, 78731
        • Rekruttering
        • Austin, Texas
      • Dallas, Texas, Forente stater, 75251
        • Rekruttering
        • Dallas, Texas
      • Frisco, Texas, Forente stater, 75033
        • Rekruttering
        • Frisco, Texas
      • Houston, Texas, Forente stater, 77070
        • Rekruttering
        • Houston, Texas
      • San Antonio, Texas, Forente stater, 78229
        • Rekruttering
        • San Antonio, Texas
      • Sugar Land, Texas, Forente stater, 77478
        • Rekruttering
        • Sugar Land, Texas

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  • 18-70 years of age
  • Body Mass Index (BMI) within the range ≥ 17.0 and ≤ 45 kg/m^2 (inclusive)
  • Meets the diagnostic criteria of Narcolepsy Type 1 (NT1) or Type 2 (NT2) according to International Classification of Sleep Disorders, 3rd edition, Text Revision edition (ICSD-3-TR) criteria
  • Is willing and able to discontinue all medications used for the treatment of narcolepsy
  • Is willing and able to adhere to additional protocol requirements

Key Exclusion Criteria:

  • Medical disorder other than NT1 or NT2, that is associated with excessive daytime sleepiness (EDS)
  • Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological or psychiatric disease

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Group A - Narcolepsy Type 1 (Dose 1)

Oral cleminorexton capsule

Eksperimentell: Group A - Narcolepsy Type 1 (Dose 2)

Oral cleminorexton capsule

Placebo komparator: Group A - Narcolepsy Type 1 (placebo)

matching placebo capsule

Eksperimentell: Group B - Narcolepsy Type 2 (Dose 1)

Oral cleminorexton capsule

Eksperimentell: Group B - Narcolepsy Type 2 (Dose 2)

Oral cleminorexton capsule

Placebo komparator: Group B - Narcolepsy Type 2 (placebo)

matching placebo capsule

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Change from baseline in mean sleep latency (average of the first 4 trials) on the Maintenance of Wakefulness Test (MWT)
Tidsramme: Baseline to week 12
Baseline to week 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline in Epworth Sleepiness Scale (ESS) total score
Tidsramme: Baseline to Week 12
Baseline to Week 12
Incidence, Severity, and casual relationship of participants with Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Baseline to Week 12
Baseline to Week 12
Number of participants with abnormal changes from baseline in clinical laboratory tests
Tidsramme: Baseline to Week 12
Baseline to Week 12
Number of participants with abnormal changes from baseline in vital signs
Tidsramme: Baseline to Week 12
Baseline to Week 12
Number of participants with abnormal changes from baseline in 12-lead electrocardiograms (ECGs)
Tidsramme: Baseline to Week 12
Baseline to Week 12
Number of participants with at least 1 endorsement of Item 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsramme: Baseline to Week 12
Baseline to Week 12
Cmax: Maximum observed plasma concentration
Tidsramme: Baseline to Week 12
Baseline to Week 12
Tmax: Time of Maximum Concentration for cleminorexton
Tidsramme: Baseline to Week 12
Baseline to Week 12
AUC: Area under the plasma concentration-time curve
Tidsramme: Baseline to Week 12
Baseline to Week 12
Weekly Cataplexy Rate (WCR)
Tidsramme: Week 12

Measurement specific to Group A

Week 12
Change from baseline in Narcolepsy Severity Scale for Clinical Trials (NSS-CT)
Tidsramme: Baseline to Week 12

Measurement specific to Group A

Baseline to Week 12
Change from baseline in Narcolepsy Severity Scale-2 for Clinical Trials (NSS2-CT) total score
Tidsramme: Baseline to Week 12

Measurement specific to Group B

Baseline to Week 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. mai 2026

Primær fullføring (Antatt)

30. september 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

27. april 2026

Først innsendt som oppfylte QC-kriteriene

13. mai 2026

Først lagt ut (Faktiske)

20. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere